Expert Interview
A look at the data presented at the ESMO 2022 Conference for the CXCR2 antagonist, AZD5069, in combination with enzalutamide for patients with metastatic castration resistant prostate cancer(mCRPC)
Ticker(s): AZN, PFEInstitution : Baptist Hospital SE Texas
- Urologist who treats 5 metastatic prostate cancer patients
- Urology residency completed at UTMB Galveston and Reconstruction Urology fellowship was competed at Columbia University
- Published in 22 Urology papers and has given 72 presentations at national meetings
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
